INSM Key Statistics, Chart & Performance
The current stock price of INSM is 161.42 USD. In the past month the price decreased by -18.66%. In the past year, price increased by 122.62%.
INSM Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to INSM. When comparing the yearly performance of all stocks, INSM is one of the better performing stocks in the market, outperforming 93.8% of all stocks.
INSM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to INSM. The financial health of INSM is average, but there are quite some concerns on its profitability.
INSM Financial Highlights
Over the last trailing twelve months INSM reported a non-GAAP Earnings per Share(EPS) of -6.19. The EPS decreased by -11.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.15% | ||
| ROE | -125.2% | ||
| Debt/Equity | 0.77 |
INSM Forecast & Estimates
25 analysts have analysed INSM and the average price target is 217.87 USD. This implies a price increase of 34.97% is expected in the next year compared to the current price of 161.42.
For the next year, analysts expect an EPS growth of -13.3% and a revenue growth 47.16% for INSM
INSM Ownership
INSM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.44B |
Related stock screener links
About INSM
Company Profile
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,271 full-time employees. The firm is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
Company Info
INSMED INC
700 Us Highway 202/206
Bridgewater NEW JERSEY 08807 US
CEO: William H. Lewis
Employees: 1271
Phone: 19089779900
INSMED INC / INSM FAQ
Can you describe the business of INSMED INC?
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,271 full-time employees. The firm is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
Can you provide the latest stock price for INSMED INC?
The current stock price of INSM is 161.42 USD. The price increased by 1.35% in the last trading session.
Does INSMED INC pay dividends?
INSM does not pay a dividend.
How is the ChartMill rating for INSMED INC?
INSM has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of INSM stock?
INSMED INC (INSM) operates in the Health Care sector and the Biotechnology industry.
When does INSMED INC (INSM) report earnings?
INSMED INC (INSM) will report earnings on 2026-02-18, after the market close.
What is the Short Interest ratio of INSMED INC (INSM) stock?
The outstanding short interest for INSMED INC (INSM) is 4.23% of its float.